hGH fragment is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-06-07. Numbers and descriptions here follow the published literature rather than marketing material.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
| Property | Value | Notes |
|---|---|---|
| Common name | AOD-9604 | Development code used in scientific literature. |
| Chemical class | Synthetic peptide | Fragment of human growth hormone. |
| Amino acid length | 16 residues | Matches hGH region 176-191. |
| Appearance | White to off-white powder | Typical lyophilized peptide solid. |
| Solubility | Soluble in water | Dissolves in aqueous media; exact behavior depends on salt form. |
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
Peripherally selective trans-3,4-dimethyl-4-(3-hydroxylphenyl)piperidine opioid antagonists were developed for the treatment of gastrointestinal motility disorder by Zimmerman and his coworkers. From that, they derived the 4-(3-hydroxyphenyl)-3,4-dimethylpiperidine scaffold with functional groups spanning various sizes, charge, and polarity to reach peripheral opioid receptor antagonism while decreasing CNS drug exposure. The in vitro μ-Ki, in vivo AD50, and ED50 and peripheral index (ratio) was examined for several selective analogs, and from that, they found out that the trans-3,4-dimethyl-4-(3-hydroxyphenyl) piperidine, Alvimopan, gave the best results. The large zwitterionic structure and the high polarity prevents Alvimopan from crossing the blood–brain barrier, potency at binding peripheral MORs is thereby 200 times that of central MORs.
==== Science and Technology Center ==== The Science and Technology Center (S/T) is a highly challenging four-year curriculum which provides college-level academic experiences in science, mathematics, and technology. The program is not a true magnet program, as students are admitted into the S/T program based on competitive examination only, as opposed to the standard magnet lottery process. Of twenty-eight possible credits, a student is required to obtain a minimum of thirteen credits in specific mathematics, pre-engineering technology, research and science courses. In grades nine and ten, the program consists of common experiences courses for all student. In grades eleven and twelve, each student must choose course work from at least one of four major study areas. Students are expected to be enrolled in a full schedule of classes during the entire four-year program. External experiences are possible and encouraged, but must be a direct extension or enrichment of the Science and Technology Program, and have the recommendation of the Science and Technology Center Coordinator prior to approval by the principal. The program is offered at three centers — Eleanor Roosevelt High School in northern Prince George's County, Oxon Hill High School in southern Prince George's County, and Charles Herbert Flowers High School in central Prince George's County. Students attend the center that serves their legal residence. Transportation is provided for all students. Each school is a four-year comprehensive high school, as well as a Science and Technology Center.
Domino's announced on February 7, 2025, that it plans to close more than 200 stores worldwide, 172 of them just in Japan, where Domino's Pizza Japan operates 1,000 stores. The decision comes after CEO and Managing Director Mark van Dyck took the reins of the company. The reason given for the closure was low sales in the selected stores. Of all the markets that include the brand, Australia–New Zealand was the only market to report positive growth. With the closures, Domino's expects to reduce costs by approximately $9.8 million.
Sources: en.wikipedia.org
TMEM125 has two variant transcripts that differ only in the 5' untranslated region (UTR), but both encode the same protein. mRNA variant 1 represents the longer of the two variants and is 1898 base pairs (bp) in length; variant 2 is 1797 bp long. TMEM125 microarray-assessed expression patterns in normal human tissue demonstrate the primary tissues of expression are the pancreas, lungs, salivary glands, trachea, brain, prostate, spinal cord, and thyroid. Additionally, RNA-seq data illustrates transcript expression in the following additional tissue: colon, small intestines, prostate, and stomach. TMEM125 comprises 219 amino acids with four transmembrane domains. Its predicted isoelectric point is 8.32 and predicted molecular weight is 22.1 kDa. It is primarily leucine-rich, and secondarily alanine- and glycine-rich; TMEM125 is also arginine- and lysine-deficient. It has two core repeat blocks, VALL and TTSS, which both appear twice within the protein. The secondary structure of TMEM125 is predicted to consist of α-helices and small segments of β-sheets.
D-Ribose-L-cysteine functions as a cysteine prodrug, delivering cysteine in a chemically protected form that may resist premature oxidation. After cellular uptake, enzymatic cleavage releases free L-cysteine, which can then enter the γ-glutamyl cycle for glutathione synthesis. This mechanism differs from N-acetylcysteine, which relies on de-acetylation and exhibits different absorption and metabolic characteristics. While both compounds ultimately increase cysteine availability, direct comparative data in humans remain limited. D-Ribose-L-cysteine is regulated in the United States as a dietary supplement ingredient, not as a pharmaceutical drug. Products containing D-ribose-L-cysteine are subject to dietary supplement regulations under the Dietary Supplement Health and Education Act of 1994 (DSHEA), which prohibit claims that a product can diagnose, treat, cure, or prevent disease. No pharmaceutical drug approvals or therapeutic indications have been granted for D-ribose-L-cysteine by the U.S. Food and Drug Administration.
Naturally occurring europium (63Eu) is composed of two isotopes, 151Eu and 153Eu, with 153Eu being the more abundant (52.2% natural abundance). While 153Eu is observationally stable, 151Eu was found in 2007 to be unstable and undergo alpha decay; its measured half-life of 4.6 × 1018 years corresponds to 1 alpha decay per two minutes per kilogram of natural europium, so for practical purposes it can be considered stable. Besides the natural radioisotope 151Eu, artificial radioisotopes from 130Eu to 170Eu have been made, with the most stable being 150Eu with a half-life of 36.9 years, 152Eu with a half-life of 13.517 years, 154Eu with a half-life of 8.592 years, and 155Eu with a half-life of 4.742 years. All the others have half-lives shorter than 100 days, with the majority shorter than 3 minutes. This element also has 27 metastable isomers, with the most stable being 150mEu (12.8 hours), 152m1Eu (9.3116 hours) and 152m5Eu (96 minutes). The primary decay mode for isotopes lighter than 153Eu is electron capture to samarium isotopes, and the primary mode for heavier isotopes is beta minus decay to gadolinium isotopes. 152Eu and 154Eu can decay either way, as can 150mEu (meta state only).
5 September – Astronomers identify a vast, bubble-like structure known as Hoʻoleilana in the distribution of relatively nearby galaxies, estimated at 1 billion light-years in diameter and described as the first observation of an individual baryon acoustic oscillation. 6 September The discovery of specialized astrocytes that mediate glutamatergic gliotransmission in the central nervous system is announced. Geologists report the discovery of what may be the largest known deposit of lithium, located in the crater of a dormant volcano along the Nevada–Oregon border, and estimated to contain 20 to 40 million tonnes of the metal. 7 September A university reports a study (24 Aug) that builds a theory linking a reduction in prey size in the Paleolithic to the evolution of technologies and cognitive abilities as they had to change their behaviors, abilities, weapons, and strategies. An NSF review on sleep provides the first consensus statement with data and preliminary observational studies-based conclusions on the importance of sleep timing regularity regarding health and performance. 11 September – The James Webb Space Telescope detects carbon dioxide and methane in the atmosphere of K2-18b, a potentially habitable exoplanet around 8.6 times the mass of Earth. Webb's data suggests that it might be a hycean planet covered in oceans of water, with a hydrogen-rich atmosphere.
Sources: en.wikipedia.org
Fodor's Flashmaps New York, 1991 Fodor's See It New York City, 2004, ISBN 1-4000-1387-9 Valentine's Manual of Old New York / No. 7, Ed. Henry Collins Brown, Pub. Valentine's Manual Inc. 1922 Further reading
Fluotracen (SKF-28,175) is a tricyclic drug which has both antidepressant and antipsychotic activity. This profile of effects is similar to that of related agents like amoxapine, loxapine, and trimipramine which may also be used in the treatment of both depression and psychosis. It was believed that such duality would be advantageous in the treatment of schizophrenia, as depression is often comorbid with the disorder and usual antipsychotics often worsen such symptoms. In any case, however, fluotracen was never marketed.
=== Light scattering === Static light scattering measures the product of weight-averaged molar mass and concentration of macromolecules in solution. Given a fixed total concentration of one or more species over the measurement time, the scattering signal is a direct measure of the weight-averaged molar mass of the solution, which will vary as complexes form or dissociate. Hence the measurement quantifies the stoichiometry of the complexes as well as kinetics. Light scattering assays of protein kinetics is a very general technique that does not require an enzyme.
Sources: en.wikipedia.org
AOD-9604 is a synthetic peptide fragment of human growth hormone. It corresponds to the C-terminal region known as hGH 176-191 and is studied for metabolic effects. It is not an approved therapeutic drug.
No. It contains only a small portion of the human growth hormone sequence. The full hormone has 191 amino acids and many additional actions that the fragment does not share.
The name refers to the amino acid positions in the human growth hormone chain. The fragment spans residues 176 through 191 at the C-terminal end. This naming convention helps distinguish it from full-length hGH.
It is a synthetic peptide based on a C-terminal fragment of human growth hormone. It is commonly referred to as hGH fragment 176-191 and is studied for metabolic effects rather than growth effects.